Summary
The possibility of a pharmacokinetic interaction between femoxetine and cimetidine has been evaluated in 8 healthy volunteers. Two volunteers received single doses of femoxetine, and 6 were given multiple doses of femoxetine for 7 days with and without concurrent cimetidine.
No influence of cimetidine was observed on the kinetics of single doses of femoxetine, but after multiple doses the plasma concentration of femoxetine was significantly increased. Similarly, the AUC at steady state tended to be increased, but not to a significant extent. Concurrent cimetidine did not cause a reduction in the AUC of the active desmethyl metabolite.
It is recommended that femoxetine is given in reduced doses (e.g. 400 mg) when administered with cimetidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buus Lassen J, Squires RF, Christensen JA, Molander L (1975) Neurochemical and pharmacological studies on a new 5HT-uptake inhibitor, FG 4963, with potential antidepressant properties, Psychopharmacologia (Berl) 42: 21–26
Buus Lassen J, Petersen E, Kjellberg B, Olsson SO (1975) Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics. Eur J Pharmacol 32: 108–115
Buus Lassen J, Squires RF (1976) Potentiation of nialamide-induced hypermotility in mice by lithium and the 5HT-uptake inhibitors chlorimipramine and FG 4963. Neuropharmacology 15: 665–668
Buus Lassen J, Squires RF (1977) Inhibition of both MAO-A and MAO-B required for the production of hypermotility in mice with the 5HT-uptake inhibitors chlorimipramine and femoxetine. Neuropharmacology 16: 485–488
Bøjholm S, Børup C, Kvist J, Petersen I-M, Le Fèvre Honoré P (1979) A double-blind study of femoxetine and amitriptyline in patients with endogenous depression. Nord Psykiat T 33: 455–460
Dahl L-E, Lundin L, le Fèvre Honoré P, Dencker SJ (1982) Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in the cerebrospinal fluid. Acta Psychiatr Scand 66: 9–17
Reebye PN, Yiptong C, Samsoon J, Schulsinger F, Fabricius J (1982) A controlled double blind study of femoxetine and amitriptyline in patients with endogenous depression. Pharmacopsychiatry 15: 164–169
Tamminen T, Salminen JK, Skrumsager BK (1982) A double-blind controlled trial of the selective serotonin uptake inhibitor femoxetine and amitriptyline in depression. Nord Psykiatr T 36: 335–339
Lund J, Christensen JA, Bechgaard E, Molander L, Larsson H (1979) Pharmacokinetics of femoxetine in man. Acta Pharmacol Toxicol 44: 177–184
Hansen BA, Mengel H, Keiding S, Lund J (1984) Femoxetine clearance in patients with liver cirrhosis. Acta Pharmacol Toxicol 55: 386–390
Larsson H, Lund J (1981) Metabolism of femoxetine. Acta Pharmacol Toxicol 48: 424–432
Klotz U, Reimann JW (1984) Drug interactions through binding to cytochrome P450: The experience with H2-receptor blocking agents. Pharm Res 2: 59–62
Hetzel D, Birkett D, Miners J (1979) Cimetidine interaction with warfarin. Lancet 2: 539
Silver BA, Bell WR (1979) Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med 90: 348–349
Wallin BA, Jacknowitz A, Raich PC (1979) Cimetidine and the effect of warfarin. Ann Intern Med 90: 993
Willoughby JMT (1979) Cimetidine. Interaction with oral anticoagulants in man. Lancet 2: 317–319
Roberts RK, Grice J, Wood L, Petroff V, McGuffie C (1981) Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology 81: 19–21
Hetzel DJ, Bochner F, Hallpike JR, Shearman DJC, Hann CS (1981) Cimetidine interaction with phenytoin. Br Med J 282: 1512
Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI (1983) Interaction of cimetidine with triazolobenzodiazepines, alprazolam and triazolam. Psychopharmacology 80: 275–278
Desmond PV, Patwardhan RV, Schenker S, Speeg KV (1980) Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med 93: 266–268
Klotz U, Reimann I (1980) Delayed clearance of diazepam due to cimetidine. N Engl J Med 302: 1012–1014
May DC, Jarboe CH, Van Bakel AB, Williams WM (1982) Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 31: 656–661
Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett LC (1984) Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther 36: 551–555
Henaner SA, Hollister LE (1983) Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther 35: 183–187
Abernethy DR, Greenblatt DJ, Shader RJ (1984) Imipraminecimetidine interaction: Impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther 229: 702–705
Amsterdam JD, Brunswick DJ, Potter L, Kaplan MJ (1984) Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology 83: 373–375
Bech P (1981) Rating scales for affective disorders: Their validity and consistency. (Thesis). Acta Psychiatr Scand 295 [Suppl]
Bechgaard E, Lund J (1977) Determination of FG 4963 in biological fluids using competition for adsorption to glass. J Chromatogr 133: 147–152
Bechgaard E, Christensen JA, Christensen O, Lund J (1978) Data transmission using frequency modulation in an automated gas chromatographic system. Anal Chim Acta 99: 189–192
Bechgaard E, Keiding S, Lund J, Christiansen LA (1983) Hepatic elimination of femoxetine in pig. Acta Pharmacol Toxicol 52: 1–7
Larsen NE, Hesselfeldt P, Rune S, Hvidberg EF (1979) Cimetidine assay in human plasma by liquid chromatography. J Chromatogr 163: 57–63
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, J., Sørensen, A.S., Gjerris, A. et al. Femoxetine and cimetidine: Interaction in healthy volunteers. Eur J Clin Pharmacol 31, 299–302 (1986). https://doi.org/10.1007/BF00981127
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00981127